The Efficacy of Using Combination Therapy against Multi-Drug and Extensively Drug-Resistant Pseudomonas aeruginosa in Clinical Settings
Published 2022 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
The Efficacy of Using Combination Therapy against Multi-Drug and Extensively Drug-Resistant Pseudomonas aeruginosa in Clinical Settings
Authors
Keywords
-
Journal
Antibiotics-Basel
Volume 11, Issue 3, Pages 323
Publisher
MDPI AG
Online
2022-03-01
DOI
10.3390/antibiotics11030323
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Time-Kill Evaluation of Antibiotic Combinations Containing Ceftazidime-Avibactam against Extensively Drug-Resistant Pseudomonas aeruginosa and Their Potential Role against Ceftazidime-Avibactam-Resistant Isolates
- (2021) María M. Montero et al. Microbiology Spectrum
- Efficacy and safety of cefiderocol or best available therapy for the treatment of serious infections caused by carbapenem-resistant Gram-negative bacteria (CREDIBLE-CR): a randomised, open-label, multicentre, pathogen-focused, descriptive, phase 3 trial
- (2020) Matteo Bassetti et al. LANCET INFECTIOUS DISEASES
- Mechanisms of ciprofloxacin resistance in Pseudomonas aeruginosa: new approaches to an old problem
- (2019) Attika Rehman et al. JOURNAL OF MEDICAL MICROBIOLOGY
- Characterization of Hypermutator Pseudomonas aeruginosa Isolates from Patients with Cystic Fibrosis in Australia
- (2019) Vanessa E. Rees et al. ANTIMICROBIAL AGENTS AND CHEMOTHERAPY
- Characterization of β-lactamase content of ceftazidime-resistant pathogens recovered during the pathogen-directed Phase 3 trial (REPRISE) for ceftazidime-avibactam: Correlation of efficacy against β-lactamase producers
- (2019) Rodrigo E. Mendes et al. ANTIMICROBIAL AGENTS AND CHEMOTHERAPY
- Colistin plus meropenem combination is synergistic in vitro against extensively drug-resistant (XDR) Pseudomonas aeruginosa, including high-risk clones
- (2019) María M. Montero et al. Journal of Global Antimicrobial Resistance
- In vitro Activity of Imipenem-Relebactam Alone or in Combination with Amikacin or Colistin against Pseudomonas aeruginosa
- (2019) Tomefa E. Asempa et al. ANTIMICROBIAL AGENTS AND CHEMOTHERAPY
- Antibiotic resistance in Pseudomonas aeruginosa – mechanisms, epidemiology and evolution
- (2019) João Botelho et al. DRUG RESISTANCE UPDATES
- EFFICACY OF CEFTAZIDIME-AVIBACTAM IN MONOTHERAPY OR COMBINATION THERAPY AGAINST CARBAPENEM RESISTANT GRAM NEGATIVE ORGANISMS: A META-ANALYSIS
- (2019) Lorenzo Onorato et al. INTERNATIONAL JOURNAL OF ANTIMICROBIAL AGENTS
- Carbapenem-resistant Pseudomonas aeruginosa and carbapenem use in Japan: an ecological study
- (2019) Fumitaka Terahara et al. JOURNAL OF INTERNATIONAL MEDICAL RESEARCH
- Clinical activity of ceftazidime/avibactam against MDR Enterobacteriaceae and Pseudomonas aeruginosa: pooled data from the ceftazidime/avibactam Phase III clinical trial programme
- (2018) Gregory G Stone et al. JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY
- Colistin alone versus colistin plus meropenem for treatment of severe infections caused by carbapenem-resistant Gram-negative bacteria: an open-label, randomised controlled trial
- (2018) Mical Paul et al. LANCET INFECTIOUS DISEASES
- Ceftazidime-avibactam versus meropenem in nosocomial pneumonia, including ventilator-associated pneumonia (REPROVE): a randomised, double-blind, phase 3 non-inferiority trial
- (2018) Antoni Torres et al. LANCET INFECTIOUS DISEASES
- Multidrug-Resistant Pseudomonas Infections: Hard to Treat, But Hope on the Horizon?
- (2018) Lynn Nguyen et al. Current Infectious Disease Reports
- Active monotherapy and combination therapy for extensively drug-resistant Pseudomonas aeruginosa pneumonia
- (2018) Thana Khawcharoenporn et al. INTERNATIONAL JOURNAL OF ANTIMICROBIAL AGENTS
- Antibiotic resistance in Pseudomonas aeruginosa: mechanisms and alternative therapeutic strategies
- (2018) Zheng Pang et al. BIOTECHNOLOGY ADVANCES
- Cefiderocol versus imipenem-cilastatin for the treatment of complicated urinary tract infections caused by Gram-negative uropathogens: a phase 2, randomised, double-blind, non-inferiority trial
- (2018) Simon Portsmouth et al. LANCET INFECTIOUS DISEASES
- Deciphering the Evolution of Cephalosporin Resistance to Ceftolozane-Tazobactam in Pseudomonas aeruginosa
- (2018) Melissa D. Barnes et al. mBio
- The efficacy and safety of tazobactam/ceftolozane in combination with metronidazole in Japanese patients with complicated intra-abdominal infections
- (2018) Hiroshige Mikamo et al. JOURNAL OF INFECTION AND CHEMOTHERAPY
- Recent updates of carbapenem antibiotics
- (2017) Mohammed I. El-Gamal et al. EUROPEAN JOURNAL OF MEDICINAL CHEMISTRY
- A randomised, double-blind, phase 3 study comparing the efficacy and safety of ceftazidime/avibactam plus metronidazole versus meropenem for complicated intra-abdominal infections in hospitalised adults in Asia
- (2017) Xinyu Qin et al. INTERNATIONAL JOURNAL OF ANTIMICROBIAL AGENTS
- Impact of combination therapy and early de-escalation on outcome of ventilator-associated pneumonia caused by Pseudomonas aeruginosa
- (2017) Laurène Deconinck et al. Infectious Diseases
- In Vitro Activity of Ceftazidime-Avibactam Against Isolates in a Phase 3 Open-label Clinical Trial for Complicated Intra-abdominal and Urinary Tract Infections Caused by Ceftazidime-Nonsusceptible Gram-negative Pathogens
- (2016) Gregory G. Stone et al. ANTIMICROBIAL AGENTS AND CHEMOTHERAPY
- Evaluation of theIn VitroActivity of Ceftazidime-Avibactam and Ceftolozane-Tazobactam against Meropenem-Resistant Pseudomonas aeruginosa Isolates
- (2016) Deanna J. Buehrle et al. ANTIMICROBIAL AGENTS AND CHEMOTHERAPY
- The properties of spontaneous mutations in the opportunistic pathogen Pseudomonas aeruginosa
- (2016) Jeremy R. Dettman et al. BMC GENOMICS
- Ceftazidime-avibactam Versus Doripenem for the Treatment of Complicated Urinary Tract Infections, Including Acute Pyelonephritis: RECAPTURE, a Phase 3 Randomized Trial Program
- (2016) Florian M. Wagenlehner et al. CLINICAL INFECTIOUS DISEASES
- Efficacy and Safety of Ceftazidime-Avibactam Plus Metronidazole Versus Meropenem in the Treatment of Complicated Intra-abdominal Infection: Results From a Randomized, Controlled, Double-Blind, Phase 3 Program
- (2016) John E. Mazuski et al. CLINICAL INFECTIOUS DISEASES
- Ceftazidime/Avibactam and Ceftolozane/Tazobactam: Second-generation β-Lactam/β-Lactamase Inhibitor Combinations
- (2016) David van Duin et al. CLINICAL INFECTIOUS DISEASES
- Ceftazidime-Avibactam: A Novel Cephalosporin/β-Lactamase Inhibitor Combination for the Treatment of Resistant Gram-negative Organisms
- (2016) Roopali Sharma et al. CLINICAL THERAPEUTICS
- Antibiotic resistance in Pseudomonas aeruginosa and alternative therapeutic options
- (2016) Maitrayee Chatterjee et al. INTERNATIONAL JOURNAL OF MEDICAL MICROBIOLOGY
- Spotlight on ceftazidime/avibactam: a new option for MDR Gram-negative infections
- (2016) Marco Falcone et al. JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY
- Ceftolozane/tazobactam and ceftazidime/avibactam for the treatment of complicated intra-abdominal infections
- (2016) Kellie Goodlet et al. Therapeutics and Clinical Risk Management
- Polymyxin B in Combination with Antimicrobials LackingIn VitroActivity versus Polymyxin B in Monotherapy in Critically Ill Patients with Acinetobacter baumannii or Pseudomonas aeruginosa Infections
- (2015) Maria Helena Rigatto et al. ANTIMICROBIAL AGENTS AND CHEMOTHERAPY
- Colistin and doripenem combinations againstPseudomonas aeruginosa: profiling the time course of synergistic killing and prevention of resistance
- (2015) Neang S. Ly et al. JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY
- Osteoarticular infection caused by MDRPseudomonas aeruginosa: the benefits of combination therapy with colistin plus β-lactams
- (2015) Alba Ribera et al. JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY
- Genotypic Diversity within a Single Pseudomonas aeruginosa Strain Commonly Shared by Australian Patients with Cystic Fibrosis
- (2015) Anna Sze Tai et al. PLoS One
- Characteristics, risk factors and outcomes of adult cancer patients with extensively drug-resistant Pseudomonas aeruginosa infections
- (2014) G. Samonis et al. INFECTION
- Colistin in multi-drug resistant Pseudomonas aeruginosa blood-stream infections
- (2014) Nihal Martis et al. JOURNAL OF INFECTION
- Systematic Review and Meta-Analysis ofIn VitroSynergy of Polymyxins and Carbapenems
- (2013) Oren Zusman et al. ANTIMICROBIAL AGENTS AND CHEMOTHERAPY
- Ceftazidime-Avibactam: a Novel Cephalosporin/β-lactamase Inhibitor Combination
- (2013) George G. Zhanel et al. DRUGS
- Liver Abscess Caused by Multidrug-resistant Pseudomonas aeruginosa Treated with Colistin; A Case Report and Review of the Literature
- (2013) Kenichiro Yaita et al. INTERNAL MEDICINE
- Carbapenems
- (2013) Dominique Breilh et al. JOURNAL OF CHEMOTHERAPY
- Epidemiology and outcome of infections with carbapenem-resistant Gram-negative bacteria treated with polymyxin B-based combination therapy
- (2013) Robbert Crusio et al. SCANDINAVIAN JOURNAL OF INFECTIOUS DISEASES
- Influence of Multidrug Resistance and Appropriate Empirical Therapy on the 30-Day Mortality Rate of Pseudomonas aeruginosa Bacteremia
- (2012) Laura Morata et al. ANTIMICROBIAL AGENTS AND CHEMOTHERAPY
- Combination Therapy for Treatment of Infections with Gram-Negative Bacteria
- (2012) P. D. Tamma et al. CLINICAL MICROBIOLOGY REVIEWS
- Efficacy and safety of ceftazidime–avibactam versus imipenem–cilastatin in the treatment of complicated urinary tract infections, including acute pyelonephritis, in hospitalized adults: results of a prospective, investigator-blinded, randomized study
- (2012) José A. Vazquez et al. CURRENT MEDICAL RESEARCH AND OPINION
- Difficult-to-treat Gram-negative bone and joint infections: efficacy and safety of prolonged intravenous colistin
- (2012) Florent Valour et al. INTERNATIONAL JOURNAL OF ANTIMICROBIAL AGENTS
- Sudden cardiac death and tuberculosis – How much do we know?
- (2012) Alexander Liu et al. TUBERCULOSIS
- Carbapenems: Past, Present, and Future
- (2011) Krisztina M. Papp-Wallace et al. ANTIMICROBIAL AGENTS AND CHEMOTHERAPY
- Effective Antibiotics in Combination against Extreme Drug-Resistant Pseudomonas aeruginosa with Decreased Susceptibility to Polymyxin B
- (2011) Tze-Peng Lim et al. PLoS One
- Pseudomonas aeruginosa: all roads lead to resistance
- (2011) Elena B.M. Breidenstein et al. TRENDS IN MICROBIOLOGY
- Pseudomonas Aeruginosa: Resistance to the Max
- (2011) Keith Poole Frontiers in Microbiology
- Colistin‐Tobramycin Combinations Are Superior to Monotherapy Concerning the Killing of BiofilmPseudomonas aeruginosa
- (2010) Gloria Herrmann et al. JOURNAL OF INFECTIOUS DISEASES
- The Accessory Genome of Pseudomonas aeruginosa
- (2010) V. L. Kung et al. MICROBIOLOGY AND MOLECULAR BIOLOGY REVIEWS
- Molecular Epidemiology and Mechanisms of Carbapenem Resistance in Pseudomonas aeruginosa
- (2009) J.-M. Rodriguez-Martinez et al. ANTIMICROBIAL AGENTS AND CHEMOTHERAPY
- Colistin therapy for microbiologically documented multidrug-resistant Gram-negative bacterial infections: a retrospective cohort study of 258 patients
- (2009) Matthew E. Falagas et al. INTERNATIONAL JOURNAL OF ANTIMICROBIAL AGENTS
- Potential for underdosing and emergence of resistance in Acinetobacter baumannii during treatment with colistin
- (2008) M. D. David et al. JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY
Publish scientific posters with Peeref
Peeref publishes scientific posters from all research disciplines. Our Diamond Open Access policy means free access to content and no publication fees for authors.
Learn MoreCreate your own webinar
Interested in hosting your own webinar? Check the schedule and propose your idea to the Peeref Content Team.
Create Now